Home > Boards > US OTC > Delisted > Intellicell Biosciences, Inc. (fka SVFC)

Here is the way I see it. Every

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
ImOnABoat Member Profile
Member Level 
Followed By 533
Posts 9,644
Boards Moderated 2
Alias Born 05/02/09
160x600 placeholder
Incyte Says Withdrawing NDA for Parsaclisib Is a 'Business Decision'
By Stephen Nakrosis
Top Company News of the Day
Texas Instruments 1Q Guidance Above Wall Street Targets
Texas Instruments' 4Q Profit, Revenue Growth Beat Wall Street Targets
Blackstone Real Estate Income Trust Offering $60 Billion in Stock in Revised Filing
2-Year Treasury Yield Rises to 1.025% -- Data Talk
10-Year Treasury Yield Rises to 1.784% -- Data Talk
30-Year Treasury Yield Rises to 2.129% -- Data Talk
Wheat Rises Further on Russia-Ukraine Tensions - Daily Grain Highlights
Front Month Nymex Natural Gas Rose 0.65% to Settle at $4.0530 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 2.56% to Settle at $2.4595 -- Data Talk
Wells Fargo Boosts Dividend
Ericsson 4Q Sales, Net Beat Expectations, ADRs Up
NextEra Energy Shares Down 7% After Revenue Misses Estimates
PayPal on Track for Lowest Close Since June 2020 -- Data Talk
Southern California Gas to Invest $50 Million Into Communities It Serves
STOXX Europe 600 Index Ends 0.71% Higher at 459.59 -- Data Talk
FTSE 100 Index Ends 1.02% Higher at 7371.46 -- Data Talk
DAX Ends 0.75% Higher at 15123.87 -- Data Talk
CAC 40 Index Ends 0.74% Higher at 6837.96 -- Data Talk
STOXX Europe 50 Index Ends 0.83% Higher at 3676.16 -- Data Talk
EURO STOXX 50 Index Ends 0.59% Higher at 4078.26 -- Data Talk
U.S. Crude-Oil Stockpiles Likely Declined in DOE Data, Analysts Say
Air Liquide to Supply Semiconductor Manufacturing Site in Arizona
FTSE 100 Finishes Higher, Clinging Onto Rebound
Norfolk Southern Raises Quarterly Dividend to $1.24 per Share
General Electric Down 7% After Revenue Miss
Eaton Corp. on Track for Largest Percent Decrease in Nearly a Year -- Data Talk
France Sells EUR3 Billion in New July 2053 OATei, Gets Strong Demand -- Update
American Express Up Over 6%, on Pace for Largest Percent Increase Since November 2020 -- Data Talk
Immix Biopharma Sees Positive Data for Pancreatic Cancer Treatment in Mouse Trial
U.S. Mid-Atlantic Factory Activity Lost Momentum in January -- Richmond Fed
ImOnABoat Member Level  Monday, 01/27/14 03:22:09 PM
Re: cccc17 post# 46204
Post # of 91005 
Here is the way I see it. Every company needs a respectable home office and, in the case of biotech companies, ideally a flagship clinic as well. Maintaing the two of those can be extremely expensive and burdensome upon the balance sheet of a startup. So the Doc essentially harbored Intellicell at the building of his fancy and popular dermatology practice in NYC. Yes, Intellicell has to pay 40% of the rent, but since the company is not yet generating any significant revenue, the rent is actually being paid out of the Doctor's pocket, and the 60% Intellicell owes back to him gets written down on the balance sheet as debt. Albeit, it is INTERNAL debt, to the Doc himself, and is not dangerous in any way (nobody will come knocking on the door like IR).

Read my thoughts on Intellicell's debt in general in this post:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95507296

That one post that BBW is so proud of about the expenses spent on setting up the clinic with furniture is, in my opinion, a testament to the company being thoughtful and financing a fantastic-looking flagship clinic in the heart of NYC - a place worthy of a company with global ambitions. See pictures of the office below:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90893527


They smartly created a home office to which it is not embarrassing to invite the investment bankers for negotiations. Perhaps this is exactly where the folks from Eilon were filling out that paperwork? Read more about it here:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=96350468

The only thing that is not optimal about Intellicell's relationship with Regen is that while Intellicell's technology is being used at the clinic, no revenue is actually attributed to Intellicell as of the last filing (keep in mind that it can change as soon as the next filing - changing fiscal year dates in the recent 8-K was an interesting sign). Also, feasible reasons do exist why a company would want to postpone showing revenue in the developmental stage.

I hope that helps.


This post is my personal opinion. I do not provide investment advice.

i.t.m.d.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences